Efavirenz/lamivudine/tenofovir

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Whywhenwhohow (talk | contribs) at 06:03, 26 March 2020 (update templates, portals, cats). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Efavirenz/lamivudine/tenofovir
Combination of
EfavirenzNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
TenofovirNucleoside reverse transcriptase inhibitor
Clinical data
Trade namesTelura
Routes of
administration		By mouth
ATC code

Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Telura, is a fixed dose combination medication for the treatment of HIV/AIDS.[1] It combines efavirenz, lamivudine, and tenofovir.[1] As of 2019 it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir.[2] It is taken by mouth.[1]

Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.[1] Severe side effects may include depression, psychosis, or osteonecrosis.[1] In those with a history of epilepsy, it may increase the frequency of seizures.[1] Greater care should also be taken in those with kidney problems.[1] It is unclear if use during pregnancy is safe.[1][3]

It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.[4] A year of medication is estimated to costs 154 USD in the developing world as of 2011.[1] The combination received tentative approval in the United States in 2014.[5] Its availability and importance is supported by Medecins Sans Frontieres.[1]

References

  1. ^ a b c d e f g h i j "Efavirenz + lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults". World Health Organization (WHO).
  2. ^ World Health Organization (July 2019). Policy brief: update of recommendations on first- and second-line antiretroviral regimens. World Health Organization. hdl:10665/325892. WHO/CDS/HIV/19.15. License: CC BY-NC-SA 3.0 IGO.
  3. ^ "Telura" (PDF). Mylan.in. 2014. Retrieved 13 December 2017.
  4. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. ^ "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". FDA. Retrieved 13 December 2017.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Efavirenz/lamivudine/tenofovir&oldid=947423546"